149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8200
https://www.protagenic.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 1
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Garo H. Armen Ph.D. | Co-Founder & Executive Chairman of the Board | N/D | N/D | 1953 |
Dr. Alexander Kenneth Arrow C.F.A., M.D. | CFO & Secretary | 150k | N/D | 1971 |
Dr. Andrew Slee Ph.D. | Chief Operating Officer | N/D | N/D | 1950 |
Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer & Director | N/D | N/D | 1951 |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
La calificación ISS Governance QuickScore de Protagenic Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.